ArticleOncology letters2025
Chromophobe renal cell carcinoma with sarcomatoid change: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chromophobe renal cell carcinoma with nodal involvement: A rare case report highlighting unusual molecular features.Urology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromophobe renal cell carcinoma (ChRCC) is a rare type of kidney cancer that is generally associated with a favorable prognosis. By contrast, RCC with sarcomatoid transformation exhibits a more aggressive clinical course, with its pathogenesis remaining largely unclear. The present study reports a case of ChRCC with sarcomatoid changes. A 54-year-old woman presented to the Department of Urology for evaluation of an incidentally detected left renal mass. Histological examination of the resected tumor revealed two distinct components: One with conventional ChRCC morphology and the other comprising highly pleomorphic, poorly differentiated cells. Next-generation sequencing of the two components revealed chromosomal losses in multiple chromosomes and variations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.